Literature DB >> 10980272

EP 60761 and EP 50885, two hexarelin analogues, induce penile erection in rats.

M R Melis1, S Succu, M S Spano, V Locatelli, A Torsello, E E Muller, R Deghenghi, A Argiolas.   

Abstract

The effect of hexarelin and four related peptide analogues, EP 40904, EP 40737, EP 50885 and EP 60761, injected into the paraventricular nucleus of the hypothalamus of male rats in doses between 2 and 2000 ng on spontaneous penile erection was studied. Of these peptides, EP 60761 and EP 50885, but not hexarelin, EP 40904 or EP 40737, increased dose-dependently the number of spontaneous penile erections. EP 60761 was active already at the dose of 20 ng, which induced the sexual response in 70% of the treated rats. The maximal response was induced by 200 ng of the peptide. EP 50885 was less potent than EP 60761, with 1000 ng being the minimal effective dose and 2000 ng as the dose required to induce the maximal response. At the doses used, both peptides also increased slightly the number of spontaneous yawning episodes. EP 60761- and EP 50885-induced penile erection was prevented by the oxytocin receptor antagonist [d(CH(2))(5)Tyr(Me)(2)-Orn(8)]vasotocin (0.1-1 microg) given intracerebroventricularly (i.c.v.), but not into the paraventricular nucleus (0.1-1 microg), by the competitive nitric oxide (NO) inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) given either into the paraventricular nucleus (10-20 microg) or i.c.v. (75-150 microg), by the N-type Ca(2+) channel blocker omega-conotoxin-GVIA (2-5 ng) or by the opiate morphine (1-10 microg), but not by the dopamine receptor antagonist (Z)-4-[3-[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]-1-p ipe razine-ethanol (cis-flupenthixol) (10 microg) or by the N-methyl-D-aspartic acid (NMDA) receptor antagonist (5R, 10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5, 10-imine ((+)-MK-801) (1 microg), all given into the paraventricular nucleus before either peptide. The present results show that EP 60761 and EP 50885 induced penile erection by increasing central oxytocin transmission, possibly by activating NO synthase in the cell bodies of oxytocinergic neurons located in the paraventricular nucleus that control penile erection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980272     DOI: 10.1016/s0014-2999(00)00481-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.

Authors:  A Aversa; M Pili; A Fabbri; E Spera; G Spera
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

Review 2.  Looking to the future for erectile dysfunction therapies.

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Central nervous system-acting agents and the treatment of erectile and sexual dysfunction.

Authors:  Culley C Carson
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 3.092

Review 4.  Central nervous system agents in the treatment of erectile dysfunction: how do they work?

Authors:  J Allard; F Giuliano
Journal:  Curr Urol Rep       Date:  2001-12       Impact factor: 2.862

Review 5.  Future prospects in the treatment of erectile dysfunction: focus on avanafil.

Authors:  Amjad Alwaal; Raed Al-Mannie; Serge Carrier
Journal:  Drug Des Devel Ther       Date:  2011-10-18       Impact factor: 4.162

6.  The stereoselectivity and hydrolysis efficiency of recombinant D-hydantoinase from Vigna angularis Against 5-benzylhydantoin derivatives with halogen and methyl substituents.

Authors:  Gniewomir Latacz; Katarzyna Kieć-Kononowicz
Journal:  Appl Biochem Biotechnol       Date:  2014-10-24       Impact factor: 2.926

Review 7.  Erectile Function and Sexual Behavior: A Review of the Role of Nitric Oxide in the Central Nervous System.

Authors:  Maria Rosaria Melis; Antonio Argiolas
Journal:  Biomolecules       Date:  2021-12-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.